SL
KRYS icon

Salomon & Ludwin’s Krystal Biotech KRYS Stock Holding History

Salomon & Ludwin’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.5K Buy
201
+18
+10% +$4.79K ﹤0.01% 462
2025
Q4 		$44.8K Buy
183
+1
+0.5% +$210 ﹤0.01% 442
2025
Q3 		$33.4K Buy
+182
New +$27.2K ﹤0.01% 523

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Salomon & Ludwin's KRYS Position: Q1 2026 in Review

Salomon & Ludwin increased its Krystal Biotech (KRYS) stake by 9.8% in Q1 2026, buying an estimated $4.79K and bringing the position to 201 shares worth $52.5K. The position accounts for ﹤0.01% of the portfolio, ranked #462.

Salomon & Ludwin first reported a position in KRYS in Q3 2025 and has held it in 3 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Salomon & Ludwin held 201 shares of Krystal Biotech worth $52.5K as of Q1 2026.
  • Salomon & Ludwin bought 18 Krystal Biotech shares in Q1 2026, an estimated $4.79K.
  • Krystal Biotech made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #462 holding.
  • Salomon & Ludwin first reported a position in Krystal Biotech in Q3 2025 and has held it in 3 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.